KRAS and non-small cell lung carcinoma: Cyclin‐dependent kinases 4 and 6 are important for KRAS‐driven oncogenesis and thus can be a putative target in NSCLC.115 Abemaciclib, a CDK4/6 inhibitor, showed promising data in patients with KRAS mutation.